Symbols / NERV $7.83 +1.82%
NERV Chart
About
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 338.84M |
| Enterprise Value | 69.71M | Income | -293.42M | Sales | — |
| Book/sh | -12.66 | Cash/sh | 7.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -16.31 | PEG | — |
| P/S | — | P/B | -0.62 | P/C | — |
| EV/EBITDA | -4.62 | EV/Sales | — | Quick Ratio | 35.94 |
| Current Ratio | 36.29 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.85 | EPS next Y | -0.48 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-11 07:00 | ROA | -13.97% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 43.27M |
| Shs Float | 6.32M | Short Float | 1.08% | Short Ratio | 4.08 |
| Short Interest | — | 52W High | 12.46 | 52W Low | 1.15 |
| Beta | -0.30 | Avg Volume | 114.23K | Volume | 233.35K |
| Target Price | $7.25 | Recom | Hold | Prev Close | $7.69 |
| Price | $7.83 | Change | 1.82% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.25
Mean price target
2. Current target
$7.83
Latest analyst target
3. DCF / Fair value
$7.25
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$7.83
Low
$7.00
High
$7.50
Mean
$7.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-12 | main | HC Wainwright & Co. | Neutral → Neutral | $7 |
| 2025-11-06 | main | HC Wainwright & Co. | Neutral → Neutral | $4 |
| 2025-02-26 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-11-06 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-08-07 | main | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-05-02 | main | HC Wainwright & Co. | Neutral → Neutral | $7 |
| 2024-02-27 | reit | HC Wainwright & Co. | Neutral → Neutral | $11 |
| 2023-08-02 | main | HC Wainwright & Co. | Neutral → Neutral | $11 |
| 2023-05-16 | reit | HC Wainwright & Co. | Neutral → Neutral | $8 |
| 2023-05-02 | reit | HC Wainwright & Co. | — → Neutral | $8 |
| 2023-03-09 | reit | HC Wainwright & Co. | — → Neutral | $8 |
| 2022-11-10 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2022-10-17 | down | JMP Securities | Market Outperform → Market Perform | — |
- CNS therapies firm Minerva joins Stifel 2026 virtual forum webcast - Stock Titan hu, 12 Mar 2026 11
- Minerva Neurosciences: Q4 Earnings Snapshot - KING5.com Wed, 11 Mar 2026 11
- NERV: HC Wainwright & Co. Raises Price Target to $7.00, Maintains Neutral Rating | NERV Stock News - GuruFocus hu, 12 Mar 2026 12
- Minerva readies 2026 trial for drug aimed at schizophrenia’s ‘negative’ symptoms - Stock Titan Wed, 11 Mar 2026 11
- Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most - finance.yahoo.com Mon, 16 Feb 2026 08
- NERV: 2025 net loss reached $293.4M; major financing supports pivotal Phase 3 trial for roluperidone - TradingView Wed, 11 Mar 2026 12
- Minerva Neurosciences Warns of Major Dilution Risk From Preferred Stock Conversions and Warrant Exercises - TipRanks hu, 12 Mar 2026 06
- Minerva Neurosciences Stock (NERV) Opinions on $200M Funding Deal | NERV Stock News - Quiver Quantitative ue, 21 Oct 2025 07
- Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap touched US$271m last week, benefiting both retail investors who own 55% as well as institutions - simplywall.st Mon, 16 Feb 2026 08
- Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Pr - GlobeNewswire ue, 21 Oct 2025 07
- Minerva Neurosciences stock soars after securing $200 million financing - Investing.com ue, 21 Oct 2025 07
- Minerva Neurosciences (NASDAQ:NERV) Shares Pass Above 50 Day Moving Average - Here's What Happened - MarketBeat Wed, 25 Feb 2026 08
- Minerva Neurosciences (NERV) registers $200M shelf for stock, debt and warrants - Stock Titan Wed, 11 Mar 2026 13
- Why Is Minerva Neurosciences Stock (NERV) Up 165% Today? - TipRanks ue, 21 Oct 2025 07
- Minerva Neurosciences (NERV) Advances Toward Phase 3 Trial with FDA Support - GuruFocus Wed, 11 Mar 2026 22
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | -569.92 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.03 |
| NormalizedEBITDA | 4.75M | -23.09M | -25.22M | -45.26M |
| TotalUnusualItems | 1.27M | 1.40M | 529.21K | -16.33K |
| TotalUnusualItemsExcludingGoodwill | 1.27M | 1.40M | 529.21K | -16.33K |
| NetIncomeFromContinuingOperationNetMinorityInterest | 1.44M | -30.01M | -32.11M | -49.91M |
| ReconciledDepreciation | 22.47K | 30.98K | 8.51K | 101.79K |
| EBITDA | 6.02M | -21.69M | -24.69M | -45.28M |
| EBIT | 6.00M | -21.72M | -24.70M | -45.38M |
| NetInterestIncome | -4.56M | -8.28M | -7.41M | -6.33M |
| InterestExpense | 4.56M | 8.28M | 7.41M | 6.33M |
| InterestIncome | 1.44M | 556.95K | 16.52K | |
| NormalizedIncome | 168.44K | -31.40M | -32.64M | -49.89M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 1.44M | -30.01M | -32.11M | -49.91M |
| TotalExpenses | 21.85M | 23.12M | 25.23M | 45.37M |
| TotalOperatingIncomeAsReported | -21.85M | -23.12M | -25.23M | -45.37M |
| DilutedAverageShares | 7.57M | 6.51M | 5.34M | 5.34M |
| BasicAverageShares | 7.57M | 6.51M | 5.34M | 5.34M |
| DilutedEPS | 0.19 | -4.61 | -6.01 | -9.35 |
| BasicEPS | 0.19 | -4.61 | -6.01 | -9.35 |
| DilutedNIAvailtoComStockholders | 1.44M | -30.01M | -32.11M | -49.91M |
| NetIncomeCommonStockholders | 1.44M | -30.01M | -32.11M | -49.91M |
| NetIncome | 1.44M | -30.01M | -32.11M | -49.91M |
| NetIncomeIncludingNoncontrollingInterests | 1.44M | -30.01M | -32.11M | -49.91M |
| NetIncomeContinuousOperations | 1.44M | -30.01M | -32.11M | -49.91M |
| TaxProvision | 0.00 | -1.80M | ||
| PretaxIncome | 1.44M | -30.01M | -32.11M | -51.71M |
| OtherIncomeExpense | 27.85M | 1.40M | 529.21K | -16.33K |
| OtherNonOperatingIncomeExpenses | 26.58M | |||
| GainOnSaleOfSecurity | 1.27M | 1.40M | 529.21K | -16.33K |
| NetNonOperatingInterestIncomeExpense | -4.56M | -8.28M | -7.41M | -6.33M |
| InterestExpenseNonOperating | 4.56M | 8.28M | 7.41M | 6.33M |
| InterestIncomeNonOperating | 1.44M | 556.95K | 16.52K | |
| OperatingIncome | -21.85M | -23.12M | -25.23M | -45.37M |
| OperatingExpense | 21.85M | 23.12M | 25.23M | 45.37M |
| ResearchAndDevelopment | 11.90M | 12.71M | 14.65M | 32.04M |
| SellingGeneralAndAdministration | 9.95M | 10.41M | 10.58M | 13.33M |
| GeneralAndAdministrativeExpense | 9.95M | 10.41M | 10.58M | 13.33M |
| OtherGandA | 9.95M | 10.41M | 10.58M | 13.33M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 6.99M | 6.99M | 5.34M | 5.34M |
| ShareIssued | 6.99M | 6.99M | 5.34M | 5.34M |
| TotalDebt | 0.00 | |||
| TangibleBookValue | -40.56M | -43.34M | -34.94M | -6.94M |
| InvestedCapital | -25.69M | -28.46M | -20.02M | 7.98M |
| WorkingCapital | 19.43M | 38.66M | 38.78M | 59.38M |
| NetTangibleAssets | -40.56M | -43.34M | -34.94M | -6.94M |
| CapitalLeaseObligations | 0.00 | |||
| CommonStockEquity | -25.69M | -28.46M | -20.02M | 7.98M |
| TotalCapitalization | -25.69M | -28.46M | -20.02M | 7.98M |
| TotalEquityGrossMinorityInterest | -25.69M | -28.46M | -20.02M | 7.98M |
| StockholdersEquity | -25.69M | -28.46M | -20.02M | 7.98M |
| RetainedEarnings | -395.38M | -396.82M | -366.81M | -334.70M |
| AdditionalPaidInCapital | 369.68M | 368.36M | 346.79M | 342.68M |
| CapitalStock | 699.00 | 699.00 | 534.00 | 534.00 |
| CommonStock | 699.00 | 699.00 | 534.00 | 534.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 62.84M | 85.36M | 75.11M | 69.15M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 60.00M | 82.02M | 73.73M | 66.33M |
| OtherNonCurrentLiabilities | 60.00M | 82.02M | 73.73M | 66.33M |
| NonCurrentDeferredLiabilities | 0.00 | |||
| NonCurrentDeferredTaxesLiabilities | 0.00 | |||
| CurrentLiabilities | 2.84M | 3.34M | 1.38M | 2.82M |
| CurrentCapitalLeaseObligation | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 363.18K | 590.77K | 14.83K | 0.00 |
| PayablesAndAccruedExpenses | 2.47M | 2.75M | 1.36M | 2.82M |
| CurrentAccruedExpenses | 865.82K | 944.33K | 393.08K | 965.74K |
| Payables | 1.61M | 1.81M | 969.67K | 1.85M |
| AccountsPayable | 1.61M | 1.81M | 969.67K | 1.85M |
| TotalAssets | 37.14M | 56.90M | 55.09M | 77.12M |
| TotalNonCurrentAssets | 14.87M | 14.90M | 14.93M | 14.92M |
| GoodwillAndOtherIntangibleAssets | 14.87M | 14.89M | 14.91M | 14.92M |
| OtherIntangibleAssets | 17.03K | 42.57K | 51.08K | |
| Goodwill | 14.87M | 14.87M | 14.87M | 14.87M |
| NetPPE | 5.44K | 10.88K | 16.33K | 0.00 |
| GrossPPE | 16.33K | 0.00 | ||
| OtherProperties | 16.33K | |||
| BuildingsAndImprovements | 0.00 | |||
| Properties | 0.00 | |||
| CurrentAssets | 22.27M | 42.00M | 40.16M | 62.20M |
| OtherCurrentAssets | 806.89K | 989.87K | 3.97M | 1.35M |
| RestrictedCash | 100.00K | 100.00K | 100.00K | 100.00K |
| PrepaidAssets | 1.35M | |||
| CashCashEquivalentsAndShortTermInvestments | 21.36M | 40.91M | 36.09M | 60.76M |
| CashAndCashEquivalents | 21.36M | 40.91M | 36.09M | 60.76M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -19.55M | -14.78M | -24.66M | -24.60M |
| IssuanceOfCapitalStock | 0.00 | 20.00M | 0.00 | 0.00 |
| CapitalExpenditure | -16.33K | |||
| InterestPaidSupplementalData | 0.00 | |||
| EndCashPosition | 21.46M | 41.01M | 36.19M | 60.86M |
| BeginningCashPosition | 41.01M | 36.19M | 60.86M | 25.46M |
| ChangesInCash | -19.55M | 4.82M | -24.66M | 35.40M |
| FinancingCashFlow | 0.00 | 19.60M | -5.00 | 60.00M |
| CashFlowFromContinuingFinancingActivities | 0.00 | 19.60M | -5.00 | 60.00M |
| NetOtherFinancingCharges | -396.29K | -5.00 | 60.00M | |
| ProceedsFromStockOptionExercised | 0.00 | |||
| NetCommonStockIssuance | 0.00 | 20.00M | 0.00 | 0.00 |
| CommonStockIssuance | 0.00 | 20.00M | 0.00 | 0.00 |
| InvestingCashFlow | 0.00 | 0.00 | -16.33K | 0.00 |
| CashFlowFromContinuingInvestingActivities | 0.00 | -16.33K | 0.00 | |
| NetInvestmentPurchaseAndSale | 0.00 | |||
| SaleOfInvestment | 0.00 | |||
| PurchaseOfInvestment | 0.00 | |||
| NetPPEPurchaseAndSale | 0.00 | -16.33K | 0.00 | |
| PurchaseOfPPE | 0.00 | -16.33K | 0.00 | |
| OperatingCashFlow | -19.55M | -14.78M | -24.65M | -24.60M |
| CashFlowFromContinuingOperatingActivities | -19.55M | -14.78M | -24.65M | -24.60M |
| ChangeInWorkingCapital | -320.60K | 4.94M | -4.06M | 259.33K |
| ChangeInOtherWorkingCapital | -3.12M | |||
| ChangeInOtherCurrentLiabilities | 0.00 | -111.23K | ||
| ChangeInOtherCurrentAssets | 0.00 | 3.12M | -3.12M | -36.27K |
| ChangeInPayablesAndAccruedExpense | -503.57K | 1.96M | -1.44M | -230.07K |
| ChangeInAccruedExpense | -306.10K | 1.13M | -557.83K | -1.09M |
| ChangeInPayable | -197.48K | 835.65K | -883.55K | 857.60K |
| ChangeInAccountPayable | -197.48K | 835.65K | -883.55K | 857.60K |
| ChangeInPrepaidAssets | 182.97K | -141.75K | 498.24K | 636.90K |
| OtherNonCashItems | -22.02M | 8.28M | 7.41M | 6.33M |
| StockBasedCompensation | 1.33M | 1.97M | 4.11M | 5.22M |
| AssetImpairmentCharge | 0.00 | 15.20M | ||
| AmortizationOfSecurities | 0.00 | |||
| DeferredTax | -1.80M | |||
| DeferredIncomeTax | -1.80M | |||
| DepreciationAmortizationDepletion | 22.47K | 30.98K | 8.51K | 101.79K |
| DepreciationAndAmortization | 22.47K | 30.98K | 8.51K | 101.79K |
| AmortizationCashFlow | 17.03K | 25.54K | 8.51K | 0.00 |
| AmortizationOfIntangibles | 17.03K | 25.54K | 8.51K | 0.00 |
| Depreciation | 5.44K | 5.44K | 0.00 | 101.79K |
| NetIncomeFromContinuingOperations | 1.44M | -30.01M | -32.11M | -49.91M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NERV
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|